Skip to Content
Global News Select

Becton Dickinson Sees Strong 1Q Revenue, Boosts 2021 Guidance

By Matt Grossman

 

Becton, Dickinson & Co. said Tuesday that revenue from Covid-19 testing will help power the company to a strong performance in the most recent quarter and through the full fiscal year.

Citing preliminary results, the New Jersey-based medical-technology company said it expects its first-quarter revenue will be $5.3 billion, up 25.6% year over year, amid strong demand for Covid-19 tests and better-than-expected performance in other business lines.

Analysts surveyed by FactSet had been expecting revenue of $4.68 billion in the quarter.

Revenue in the company's medical segment in the quarter is expected to be $2.3 billion, while life-sciences revenue, which includes Covid-19 testing, is expected to be $2 billion, it said.

Covid-19 testing revenue is expected to be approximately $865 million in the period, the company said. International revenue is expected to be $1 billion, the company said.

For the full 2021 fiscal year, revenue is expected to be be near the top end of its previously given guidance range, while adjusted earnings is expected to exceed the guidance, Becton Dickinson said.

In November, the company said it expected revenue growth in the high-single to low-double digits in the coming fiscal year, and adjusted earnings per share of $12.40 to $12.60.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

(END) Dow Jones Newswires

January 12, 2021 06:52 ET (11:52 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.